Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
2.770
+0.030 (1.09%)
Oct 26, 2026, 3:32 PM EDT - Market open
Upstream Bio Revenue
Upstream Bio had revenue of $773.00K in the quarter ending June 30, 2026, a decrease of -17.50%. This brings the company's total for the last twelve months to $3.16M, up 15.98% year-over-year. In the year 2025, Upstream Bio had annual revenue of $2.85M with 20.42% growth. That makes Upstream Bio the 41,346th largest company in the world by revenue and 5,567th in the United States.
Revenue (ttm)
$3.16M
Revenue Growth
+15.98%
P/S Ratio
50.99
Revenue / Employee
$42,107
Employees
75
Market Cap
151.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.85M | 484.00K | 20.42% |
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
UPB News
- 4 weeks ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 6 weeks ago - Upstream Bio presents results from VALIANT trial at ERS Congress - TheFly
- 6 weeks ago - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - GlobeNewsWire
- 7 weeks ago - Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps - TheFly
- 7 weeks ago - Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewsWire
- 2 months ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly
- 2 months ago - Upstream Bio price target raised to $9 from $8 at JPMorgan - TheFly
- 2 months ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly